Research from Chalmers University of Technology, Sweden, shows that resistant bacteria can regain susceptibility to ...

Imbrium Therapeutics L.P. ("Imbrium"), a subsidiary of Purdue Pharma L.P. ("Purdue"), today announced the first patient has been randomized and dosed in a Phase 2 clinical study evaluating sunobinop ...